2019 CYIR Finalized
17 nostic yield in the standard ENB bronchoscopic literature, but lower than the average diagnostic yield with the CT guided transthoracic needle aspiration (TTNA) approach. 3. The complication rates for ENB-CBCT-AF are consistent with the standard ENB literature, but significantly less than the com- plication rates due to CT guided TTNA. 4. This study demonstrated that ENB-CBCT-AF biopsy of periph- eral pulmonary lesions is safe and produces a high diagnostic yield. 5. Although intriguing, ENB-CBCT-AF guided biopsy may be only available to a few pulmonologist/surgeons that possess the skill and technology to utilize this diagnostic approach. ENDOBRONCHIAL ULTRASOUND: CURVILINEAR Webb TN, Flenaugh E, Martin R, Parks C, Behara RI. Effect of Routine Clopidogrel Use on Bleeding Complications After Endobronchial Ultrasound-guided Fine Needle Aspiration. J Bronchol Intervent Pulmonol 2019; 26:10–14 Summary It is not uncommon that patients being treated with anti- platelet medications (clopidogrel and aspirin) require endo- bronchial ultrasound bronchoscopy (EBUS) guided fine needle aspiration (FNA) for the investigation of mediastinal and hilar lymphadenopathy. In some of these patients, stopping these medications can lead to a substantial dan- ger of thrombotic complications. Webb et al. evaluated the risk of bleeding complication after an EBUS-guided FNA for abnormal mediastinal lymphadenopathy in patients that are unable to stop the antiplatelet medication. In this multicenter prospective trial, 40 patients being treated with clopidogrel and aspirin, unable to be withheld for the procedure, underwent EBUS guided FNA for investigation of mediastinal lymphadenopathy. An interventional pulmo- nologist performed all procedures and the first 3 samples were taken with a 22-gauge needle. If there was no signifi- cant bleeding (defined as the need for any intervention to obtain hemostasis), a 21-gauge needle was utilized for the next 3 sample collections. A total of 92 lymph nodes were sampled. There were no significant bleeding events report- ed at any of the cases or 24 hours after the procedure. Comments 1. This study is the largest multicenter; prospective study evalu- ating the safety of EBUS guided FNA for mediastinal/hilar lymphadenopathy in patients on antiplatelet medication that are unable to be held for the procedure due to the high risk of a thrombotic complication. 2. This trial was limited to interventional pulmonologists that have extensive experience in both EBUS-FNA and management of airway bleeding. 3. Based on the results of this study, in patients that are unable to stop antiplatelet medication, EBUS-guided FNA for medias- tinal/hilar lymph node sampling is safe with both 22- and 21- gauge needles. 4. There may be a role for bridging these patients with short acting medications such as glycoprotein IIb/IIIa inhibitors. Hopefully, more investigation will be done to answer this question. 5. These data certainly add to our understanding of the safety of EBUS-guided FNA in patients on antiplatelet medications, but we must take extreme caution when pursuing these biopsies. OTHER ARTICLES OF INTEREST Bhatt KM, Tandon YK, Graham R, Lau CT, Lempel JK, Azok JT, Mazzone PJ, Schneider E, Obuchowski NA, Bolen MA. Electromagnetic Navigational versus Ct-Guided Percutaneous Sampling of Peripheral Indeterminate Pulmonary Nodules: A Cohort Study. Radiology: 2018. Volume 286: Number 3. 1052-1061 Feller-Kopman DJ, Reddy CB, DeCamp MM, Diekemper RL, Gould MK, Henry T, Iyer NP, Lee YCG, Lewis SZ, Maskell NA, Rahman NM, Sterman DH, Wahidi MM, Balekian AA; on behalf of the American Thoracic Society, Society of Thoracic Surgeons, and Society of Thoracic Radiology. Management of Malignant Pleural Effusions. An Official ATS/STS/STR Clinical Practice Guideline. Am J Resp Crit Care Med 2018; 198:839-849 Bhatnagar R, Keenan EK, Morley AJ, Kahan BC, Stanton AE, Harris M, Harrison RN, Mustafa RA, Bishop LJ, Ahmed L, West A, Holme WJ, Evison HM, Munavvar M, Sivasothy P, Herre J, Cooper D, Roberts M, Guhan A, Hooper C, Walters J, Saba TS, Chakrabarti B, Gunatilake S, Psallidas I, Walker SP, Bibby AC, Smith S, Stadon LJ, Zahan-Evans NJ, Lee YCG, Harvey JE, Rahman NM, Miller RF, Maskell NA. Outpatient Talc Administration by Indwelling Pleural Catheter for Malignant Pleural Effusions. N ENGL J MED 378;14:1313-1322 Silvestri GA, Tanner NT, Kearney P, Vachani A, Massion PP, Porter A, Springmeyer SC, Fang KC, Midthum D, Mazzone P: for the PANOPTIC Trial Team. Assessment of Plasma Proteomics Biomarkers’s Ability to Distinguish Benign From Malignant Lung Nodules. Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial. CHEST 2018; 154(3):491-500 Karthik Suresh, Voong KR, Shankar B, Forde PM, Ettinger DS, Marrone KA, Kelly RJ, Hann CL, Levy B, Feliciano JL, Brahmer JR, Feller-Kopman D, Lerner AD, Lee H, Yarmus L, D’Alesso F, Hales RK, Lin CT, Psoter KJ, Danoff SK, Naidoo J. Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors. Journal of Thoracic Oncology Vol. 13 No. 12.1930-1939 INTERVENTIONAL PULMONOLOGY
Made with FlippingBook
RkJQdWJsaXNoZXIy MTM1ODMw